I've Just Been Diagnosed with Crohn's Disease — What Now?

The road to a Crohn's diagnosis is often a long one. Months or years of symptoms — cramping, diarrhoea, weight loss, fatigue — before a colonoscopy and biopsy finally gives them a name. There is something grounding about finally having an answer, even a difficult one.

Crohn's is a serious chronic condition. It is not curable. But for many people, it is highly controllable — and with the right treatment and the right scheme in place, it need not dominate your life.

What to Do Right Now: Five Steps

Step 1 — Establish your disease phenotype with your gastroenterologist

Not all Crohn's is the same. Your gastroenterologist needs to establish: - Location: ileocaecal (most common), colonic, small bowel, upper GI, perianal - Behaviour: luminal (inflammatory), stricturing (narrowing), fistulising/penetrating - Severity: HBI or CDAI score - Extra-intestinal manifestations: joints, skin, eyes

Your treatment plan depends entirely on phenotype. A patient with mild ileocaecal Crohn's on budesonide looks completely different from a patient with fistulising perianal Crohn's on biologics. Make sure your gastroenterologist documents the disease location and behaviour — this matters for CDL registration and biologic authorisation later.

Step 2 — Understand your first treatment: budesonide or prednisolone for induction

If your disease is active, you'll likely start a short course of budesonide (for ileocaecal disease) or prednisolone (for more extensive disease). These are induction agents — they bring the inflammation down but are not for long-term use. Expect 8–12 weeks on the initial course.

Steroids for Crohn's are CDL-funded. Their cost is minimal.

Step 3 — Register for CDL benefits and start azathioprine

Azathioprine (AZA) is the standard maintenance drug after induction. It takes 3–6 months to reach full effect and needs regular blood monitoring (FBC + LFTs monthly initially). It costs approximately R400/month and is fully CDL-funded. TPMT enzyme testing before starting is important — it identifies the small subset of patients who cannot safely metabolise azathioprine at standard doses.

Contact your scheme to register Crohn's as a CDL condition. Your gastroenterologist's CDL registration form is the starting document. Without CDL registration, you are claiming these medications from day-to-day benefits — a much more limited pool.

Step 4 — Check your scheme's biologic access policy now

Most newly diagnosed Crohn's patients start on azathioprine, which works well for many. But up to 40% of patients eventually need biologic therapy (anti-TNF, vedolizumab, or ustekinumab). Biologic therapy for Crohn's requires scheme exceptional needs authorisation — a process that takes weeks. Knowing your scheme's policy before you need biologics saves critical time later.

Ask your scheme: "Does your formulary include adalimumab biosimilar (AMGEVITA)? What is your exceptional needs pathway for IBD biologics?"

Step 5 — Understand that surgery is not a cure — but may still happen

Unlike ulcerative colitis, colectomy does not cure Crohn's. But many Crohn's patients (up to 50% over 10 years) require surgery for complications — bowel strictures, abscesses, or fistulae. If you need bowel resection, a colorectal surgeon is involved: this is the primary gap cover use case for Crohn's. Know your scheme's network of colorectal surgeons and your gap cover situation before you're in hospital.

Your Most Important Questions, Answered

Is Crohn's fatal? No — Crohn's does not directly cause death. Life expectancy is near-normal with modern management. Quality of life is the concern, not longevity.

Can I eat normally? Many patients manage well without strict dietary restriction. During flares, a low-residue diet reduces symptom burden. During remission, there is no single universally effective Crohn's diet — trigger foods vary significantly between individuals. A dietitian with experience in IBD is a valuable member of your care team, particularly if you have small bowel disease affecting nutrient absorption.

Will I need surgery? Not necessarily. Many patients achieve long-term remission on medication. But Crohn's complications (strictures, fistulae, abscesses) can require surgical intervention. The lifetime surgical rate is approximately 50% across all Crohn's phenotypes — but this is heavily influenced by disease behaviour and how well-controlled the condition is. Maintaining remission on effective therapy reduces long-term surgical risk.

What about work and daily life? In remission, Crohn's should not significantly impair daily functioning. During flares, abdominal pain and diarrhoea can be debilitating. Effective treatment and prompt flare management are essential to protecting work capacity. Fatigue is a common feature even in apparent remission — it is a recognised Crohn's symptom, not just a consequence of poor sleep.

What does this cost my scheme? csDMARDs (azathioprine): CDL-funded, ~R4,800/year. Biologic escalation: R60,000–R130,000/year depending on drug and biosimilar vs originator policy. Surgery adds the colorectal surgeon shortfall.

Should I change my scheme? If you are newly diagnosed and currently on a hospital plan or entry-level scheme, consider this carefully. Crohn's requires gastroenterologist access, regular colonoscopy, and potentially biologics. A scheme with a comprehensive IBD exceptional needs process and a broad gastroenterology network matters more for Crohn's than it does for simpler CDL conditions.

The Next Three Months

Your Scheme Coverage for Crohn's

csDMARDs and steroid induction are fully CDL-funded. The critical scheme variables for Crohn's: biologic formulary policy (biosimilar-first? vedolizumab or ustekinumab available under exceptional needs?) and colorectal surgery network. Both matter before you need them.

Ready to check how your scheme covers Crohn's? Run your AURA check